Skip to main content

Peer Review reports

From: Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial

Original Submission
5 Sep 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
29 Oct 2023 Reviewed Reviewer Report - Juan Manuel Sepulveda-Sanchez
8 Nov 2023 Reviewed Reviewer Report
23 Nov 2023 Author responded Author comments - Hui Dai
Resubmission - Version 4
23 Nov 2023 Submitted Manuscript version 4
1 Dec 2023 Reviewed Reviewer Report - Juan Manuel Sepulveda-Sanchez
4 Dec 2023 Reviewed Reviewer Report
14 Dec 2023 Author responded Author comments - Hui Dai
Resubmission - Version 5
14 Dec 2023 Submitted Manuscript version 5
19 Dec 2023 Reviewed Reviewer Report
19 Dec 2023 Reviewed Reviewer Report - Juan Manuel Sepulveda-Sanchez
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
20 Dec 2023 Editorially accepted
2 Jan 2024 Article published 10.1186/s12885-023-11776-4

You can find further information about peer review here.

Back to article page